Search results
139 Results for 'Genome Engineering'
- Technologies (11)
- Collaborations (0)
- Team (0)
- News (104)
- Pages (0)
- Multimedia (24)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 11
-
Ichor: Reversing Aging
Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health. -
Plastivores: Plastic-Degrading Super-Microbes and Enzymes
The Plastic Degradation project identifies microbes from natural sources that have a low-level ability to degrade multiple types of plastic. In the laboratory, with the help of synthetic biology, those microbes then are evolved into much more effective plastic-eating microbes that, in the future, could be globally deployed to decompose plastic waste. -
HarborSite: Precise and Efficient Gene Editing for Next-Generation Gene Therapies
The HarborSite next-generation gene therapy platform enables integration of therapeutic genes into genomic safe harbors using highly specific and efficient recombinases to enable more predictable, safe and durable gene therapies. -
CogniXense for Rare Disease Drug Discovery
Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome. -
Biotechnology for Conservation and De-Extinction
Colossal Biosciences is leveraging a suite of technologies including genome engineering to de-extinct critical species like the wooly mammoth to advance conservation to combat biodiversity loss. -
SomaCode: Getting Cell Therapies Where They Need to Go
SomaCode is solving the problem of cell therapy delivery by identifying unique molecular “zip codes” for disease and engineering cells to home to those zip codes, making cell therapies safer and more effective.
News 104
Multimedia 24
-
Audio/PodcastSeqVerify: A New Easily Accessible Tool for Comprehensive Cell Line Quality Assessment – The Stem Cell ReportDuring the last decade, advances in genome editing and pluripotent stem cell (PSC) culture have let researchers generate edited PSC lines to study a wide variety of biological questions. However, abnormalities in cell lines such as aneuploidy, mutations, on-target and off-target editing errors, and microbial contamination can arise during PSC culture or due to undesired... -
Video/AnimationHarborSite AnimationThis animation explains how the Wyss Institute’s HarborSite genome editing technology uses highly specific and efficient recombinase enzymes and genomic safe harbors to achieve more predictable, safe, and durable gene therapies. Credit: Wyss Institute at Harvard University -
Video/AnimationGenetic & Cellular Engineering w/ David Schaffer & Samir Mitragotri – BIOS RoundtableSamir Mitragotri is a Core Faculty member at the Wyss Institute and the Hiller Professor of Bioengineering & Hansjorg Wyss Professor of Biologically Inspired Engineering at Harvard SEAS. David Schaffer is Professor at UC Berkeley & Director at BBH. The two discuss Genetic and Cellular Engineering, with a focus on delivery challenges. -
Video/AnimationSomaCode: GPS for Cell TherapyJust like zip codes help drivers navigate to specific addresses using a GPS system, the molecular ‘zip codes’ identified via the SomaCode platform can be used to deliver cell therapies to their specific targets in the human body, increasing the therapies’ efficacy and reducing side effects. Credit: Wyss Institute at Harvard University -
Video/AnimationCogniXense: Speeding Up Treatments for Rare DiseasesAt the Wyss Institute, we are tackling Rett syndrome, a rare disease that affects 1 out of 9,000 children, by developing a scalable model for neurodevelopmental and cognitive diseases. This model can test drugs to see which will improve memory, learning, and behavior, with the end goal of finding effective therapies. Credit: Wyss Institute at... -
Video/AnimationAAV Capsid EngineeringWyss researchers have created a high-throughput platform to generate an Adeno-associated virus 2 (AAV2) library containing 200,000 variants, each carrying a distinct mutation in the virus capsid protein. Their analysis identified capsid changes that enhanced “homing” potential to specific organs in mice and virus viability, as well as a new protein hidden in the capsid-encoding...